EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a significant milestone as the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application for depemokimab,
GSK Depemokimab accepted for review by EMA for use in asthma with type 2 inflammation, CRSwNP
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The
Stopwatch starts on reviews of GSK's long-acting asthma drug
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES) that made sales of £1.3 billion in the first nine months of 2024 and is one of the company's top products.
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here.
GSK announces EMA accepted for review the MAA for depemokimab
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use
GSK applications for sinus disease treatment accepted for review
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and the EU.
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and
pharmaphorum3mon
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
National Institute for Health and Care Excellence2d
Awaiting development: Guidance and quality standards
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249 Technology appraisal guidance Datopotamab deruxtecan for ...